View Older Stories View More Recent Stories

Apr 20, 2018 06:54AM Biogen (BIIB) Reports $1B Payment to Ionis Pharma (IONS) for Expanded Collaboration on Neurological Diseases Drug Development
Apr 20, 2018 06:30AM Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
Apr 17, 2018 07:30AM Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases
Apr 5, 2018 08:11AM AbbVie (ABBV) Confirms Resolution of HUMIRA Patent Disputes with Samsung Bioepis
Apr 5, 2018 08:09AM Biogen (BIIB) & Samsung Bioepis Report Settlement with AbbVie (ABBV) for Commercialization of IMRALDI (Adalimumab Biosimilar) in Europe
Apr 5, 2018 08:05AM Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe
Mar 28, 2018 04:01PM Biogen to Report First Quarter 2018 Financial Results on April 24, 2018
Mar 15, 2018 08:00AM Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting
Mar 15, 2018 04:56AM Biogen to Present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting
Mar 12, 2018 07:30AM New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)
Mar 12, 2018 07:30AM Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia
Mar 2, 2018 05:56AM AbbVie (ABBV) & Biogen (BIIB) Report Voluntary Global Withdrawal of Marketing Authorizations for ZINBRYTA (Daclizumab)
Mar 2, 2018 05:07AM Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis
Feb 28, 2018 04:46PM Biogen to Present at the Cowen and Company 38th Annual Health Care Conference
Feb 14, 2018 05:09PM Biogen (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) Announce Published SPINRAZA (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
Feb 14, 2018 05:01PM The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
Feb 7, 2018 07:31AM Biogen (BIIB) Phase 2b Study of Natalizumab in Acute Ischemic Stroke Did Not Demonstrate Improvement in Clinical Outcomes
Feb 7, 2018 07:30AM Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke
Feb 5, 2018 04:01PM Biogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Jan 25, 2018 06:29AM Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively
Jan 4, 2018 04:01PM Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing
Dec 21, 2017 07:04AM Eisai, Biogen (BIIB) Say Phase II Study of BAN2401 Did not Meet Criteria for Success based on Bayesian Analysis at 12 Months, Study to Continue
Dec 21, 2017 07:00AM Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint
Dec 20, 2017 04:01PM Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018
Dec 19, 2017 05:38PM Biogen (BIIB) and Ionis (IONS) Enter Agreement to Identify Novel Therapies for Treatment of SMA
Dec 19, 2017 04:06PM Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
Dec 18, 2017 04:01PM Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 7, 2017 04:01PM Biogen to Present at the Guggenheim 5th Annual Healthcare Conference
Dec 4, 2017 07:30AM Biogen Appoints Mark Hernon as SVP, Chief Information Officer
Nov 27, 2017 07:02AM Biogen (BIIB) and Alkermes (ALKS) Announce Pact to Develop and Commercialize ALKS 8700 for Treatment of MS
Nov 27, 2017 07:00AM Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
Nov 27, 2017 07:00AM Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
Nov 21, 2017 07:35AM Biogen (BIIB) Names Jeff Capello as EVP and Chief Financial Officer
Nov 21, 2017 07:30AM Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer
Nov 20, 2017 04:01PM Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Nov 2, 2017 04:30PM Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation
Nov 2, 2017 07:30AM Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Nov 1, 2017 05:07PM Biogen (BIIB), Ionis (IONS) Announces NEJM Publishes First Phase 3 Study Results of SPINRAZA for Treatment of Spinal Muscular Atrophy
Nov 1, 2017 05:06PM The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
Oct 30, 2017 04:01PM Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference
Oct 27, 2017 07:50AM Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product
Oct 25, 2017 05:56AM Biogen (BIIB) Reports AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Oct 25, 2017 01:00AM Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Oct 24, 2017 06:59AM Biogen Reports Quarterly Revenues of $3.1 Billion
Oct 24, 2017 06:31AM Biogen (BIIB) Announces Amended Agreement with Neurimmune Holding AG on Investigational Alzheimer's Disease Treatment Aducanumab
Oct 24, 2017 06:29AM Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG
Oct 23, 2017 07:16AM Biogen (BIIB), Eisai Expand Pact to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab
Oct 23, 2017 07:15AM Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab
Oct 18, 2017 07:30AM Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach
Oct 10, 2017 07:03AM Align Biopharma Introduces New Technology Standard to Enable Single Sign-on for Healthcare Providers
View More Recent Stories View Older Stories